The Z0011 trial initiated a paradigm shift in the axillary treatment of breast cancer patients with a positive sentinel lymph node biopsy (SLNB), disregarding patients with a positive ultrasound-guided lymph node biopsy (UGLNB). We examined whether relevant differences exist betwe...
As we reevaluate the appropriate axillary surgery for staging in patients with node-positive breast cancer, it becomes important to consider the likelihood of nodal response and the potential advantages of utilizing sentinel lymph node surgery. Table. Results from recent clinical trials evaluating the ...
The evolving role of marked lymph node biopsy (MLNB) and targeted axillary dissection (TAD) after neoadjuvant chemotherapy (NACT) for node-positive breast cancer: systematic review and pooled analysis. Cancers (Basel). 2021;13(7):1539. doi:10.3390/cancers13071539PubMedGoogle ScholarCrossref...
1 The Role of the Oncotype DX® Assay in the Treatment Selection for ER-positive, HER2- negative and Node-positive Breast Cancer 2 Does Every ER-positive, Node-positive Patient Need Adjuvant Chemotherapy? The Oncotype DX® Assay and Node-positive Breast Cancer Case Study: Is Chemotherapy ...
Mislabeled Figures:In the Original Contribution entitled “Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer” published in the April 12, 2006, issue ofJAMA(2006;295:1658-1667), incorrect titles and legends were matched with the figures. The ...
node-positive breast cancer to test two major objectives: whether the primary outcome, disease-free survival, was longer with cyclophosphamide, doxorubicin, ... KS Albain,WE Barlow,Prof Peter M Ravdin,... - 《Lancet》 被引量: 635发表: 2009年 Randomized 2 x 2 trial evaluating hormonal treat...
Gene expression and benefit of chemotherapy in women with node-negative, oestrogen receptor-positive breast cancer. J. Clin. Oncol. 24, 3726–3734 (2006). Article CAS Google Scholar Bartlett, J. M. et al. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK...
出版年:1999-2 页数:434 定价:$ 444.09 ISBN:9780792384472 豆瓣评分 目前无人评价 评价: 写笔记 写书评 加入购书单 分享到 内容简介· ··· During the last decade, important advancements on the understanding of the molecular mechanisms involved in tumorigenesis and progression of breast cancer have bee...
Ann H. Partridge, MD, MPH, discusses unique challenges associated with very young patients who have ER+/node-positive breast cancer.
- 《British Journal of Cancer》 被引量: 253发表: 0年 Modelling the effects of standard prognostic factors in node-positive breast cancer Modelling the effects of standard prognostic factors in node- positive breast cancer. German Breast Cancer Study Group (GBSG). Br J Cancer 1999; 79: ......